Daniel Amann

Overview

Daniel Amann is an Austrian digital-health entrepreneur based in Lower Austria, known as the co-founder and commercial lead of edupression, a Klosterneuburg-based digital-therapeutics company operating under the legal entity SOFY GmbH. He co-founded the company in 2018 together with Prof. Dr. Lukas Pezawas, a psychiatry researcher at the Medical University of Vienna, to build a CE-certified, prescription-eligible digital psychotherapy programme for adults with unipolar depression and burnout. Secondary sources, including a commercial contact-database listing, describe Amann in a chief-executive-style operating role at edupression; this record treats that as unverified rather than confirmed, since no primary source reviewed states a formal title. His LinkedIn profile identifies him with "edupression.com by SOFY GmbH."

Why this matters

Amann's venture belongs to a small cohort of Austrian founders who have taken a clinically validated therapeutics product through Germany's Digitale Gesundheitsanwendungen, or DiGA, reimbursement pathway — the mechanism that lets a German-licensed physician prescribe a piece of software and statutory health insurance pay for it. Reaching and holding a permanent DiGA listing, as edupression has according to secondary sources, is a multi-year regulatory and clinical-evidence undertaking that few digital-health startups complete, which is why founders who get there draw editorial interest from a DACH startup audience even when the company itself remains small.

Career

Public sources place almost all of Amann's documented professional identity around edupression; no independently verified prior venture, employer, or founding role outside edupression is documented in the sources reviewed for this record. Industry-conference listings, including for the GIANT Health London digital-health event, describe him speaking on edupression's work; specific years attached to those listings are inconsistent across the secondary sources found and are not independently confirmed here. edupression describes its evidence base as including randomized controlled trials run with the Medical University of Vienna, work that required Amann, as the non-clinical co-founder, to build the commercial, regulatory and go-to-market infrastructure around Prof. Pezawas's clinical research programme.

Role in the ecosystem

Amann represents a founder archetype that recurs across DACH digital health: an operating entrepreneur who pairs with a credentialed clinical academic to build a company around that academic's research rather than around a pre-existing commercial idea. That division of labour — commercial founder plus clinical principal investigator — is common among the handful of DACH digital-therapeutics ventures that have reached DiGA-listed, insurance-reimbursed status. Amann has been the public commercial face of edupression in interviews and at industry events, while Prof. Pezawas has represented its clinical-evidence side.

Selected relationships

Co-founder: Prof. Dr. Lukas Pezawas, Medical University of Vienna psychiatry department, edupression's clinical principal investigator. Company: edupression, operated under the legal entity SOFY GmbH, Klosterneuburg, Lower Austria, Austria — see Startuprad.io's separate entity record for edupression for company-level detail on its product, regulatory status and clinical evidence. No investor relationships for Amann personally are documented in the sources reviewed; secondary databases describe edupression itself as bootstrapped, with academic and public-innovation-programme support rather than institutional venture funding.

Startuprad.io relevance

Startuprad.io interviewed Daniel Amann as a founder guest covering edupression for its DACH digital-health reporting. The original interview published in October 2021 and was refreshed and republished as a founder-interview episode in March 2026.

Public source context

Sources reviewed for this record include Amann's LinkedIn profile, edupression's own legal and product pages, a brutkasten article on edupression's therapy programme, a GIANT Health London speaker listing, a commercial contact-database entry (used only for the unverified operating-role claim flagged above), and the two Startuprad.io coverage items listed below. No claim in this record is corroborated by more than one primary source unless stated.

Startuprad.io coverage

Meet Edupression a Vienna-based App on Prescription — Founder Interview
Published: 15 March 2026
Last updated: 20 September 2026
Coverage type: Interview
https://www.startuprad.io/post/meet-edupression-a-vienna-based-app-on-prescription-founder-interview

Meet Edupression a Vienna-Based App on Prescription
Published: 13 October 2021
Last updated: 20 September 2026
Coverage type: Interview
https://www.startuprad.io/post/meet-edupression-a-vienna-based-app-on-prescription

There is more to this story
For Entrepreneurs Vault members, I go one level deeper: what edupression's DiGA reimbursement path reveals about the economics of prescription digital therapeutics
We look at how the German DiGA pricing and reimbursement mechanism actually works for a bootstrapped founder team, why clinically-validated software can reach patients without a pharma-scale balance sheet, and what that means for founders and operators building regulated digital-health products.
The full Entrepreneurs Vault analysis is available to members.
▶ Join on YouTube: https://www.youtube.com/startupradio/join
✉️ Join on Substack: https://startupradio.substack.com/subscribe

Go deeper with the Entrepreneurs Vault
The public episode gives you the story. Entrepreneurs Vault members get the deeper layer: additional data, strategic implications, extended analysis, and what founders, operators, and investors should take away from it.
Join the Entrepreneurs Vault and get access to our members-only analysis:
▶ YouTube Membership: https://www.youtube.com/startupradio/join
✉️ Substack: https://startupradio.substack.com/subscribe

About Startuprad.io
Startuprad.io is a European B2B media, data and intelligence platform. It provides structured entity and ecosystem data, source-backed research, datasets and AI/training-data solutions, as well as strategic visibility and access to a professional European audience of founders, investors, executives and B2B decision-makers.

Organizations use Startuprad.io for intelligence and research, structured data and AI applications, executive and company positioning, and trusted B2B reach across Europe.